Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ciaran Smythe

General Practice Aventura, FL Doctor of Osteopathy

NPI 1093274318 CMS profile 11345429

2925 Ne 199Th St Ste 205, Aventura, FL 33180

Open in the dashboard

General payments

$23,697

375 records reported · program years 2022–2025

Research payments

$658

Paid to them · 6 records reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ciaran Smythe of Aventura, FL is reported in the CMS Open Payments database as having received $23,697 across 375 general payments and $658 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,501 138
2025 Research $658 6
2024 General $11,501 169
2023 General $3,320 60
2022 General $375 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ciaran Smythe
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Ciaran Smythe were reported at $8,501. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Ciaran Smythe General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $0 $93 $30–$272 $132
2022 $375 $103 $36–$279 $149
2023 $3,320 $106 $34–$276 $160
2024 $11,501 $114 $39–$290 $164
2025 $8,501 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $3,363 47 payments
  2. Genzyme Corporation $2,366 42 payments
  3. Janssen Scientific Affairs, LLC $2,258 11 payments
  4. Lilly USA, LLC $1,399 24 payments
  5. Almirall LLC $1,268 24 payments
  6. Arcutis Biotherapeutics, Inc. $1,199 24 payments
  7. Novartis Pharmaceuticals Corporation $1,160 18 payments
  8. Incyte Corporation $1,132 22 payments
  9. UCB, Inc. $1,114 16 payments
  10. Sun Pharmaceutical Industries Inc. $1,073 18 payments
  11. Other $7,365 129 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $21,129 363 payments
  2. Consulting Fee $1,103 1 payment
  3. Travel and Lodging $1,029 5 payments
  4. Education $436 6 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $2,046 32 payments
  2. DUPIXENT $1,605 30 payments
  3. NATRELLE SALINE-FILLED BREAST IMPLANTS $1,446 9 payments
  4. Bimzelx $1,102 15 payments
  5. Klisyri $1,076 17 payments
  6. OPZELURA $1,006 21 payments
  7. COSENTYX $903 15 payments
  8. ILUMYA $901 13 payments
  9. CIBINQO $820 19 payments
  10. Zoryve $766 19 payments
  11. Other $10,331 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2022–2025
  1. Regeneron Pharmaceuticals, Inc. $658 6 payments

Records

381 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record